Remus Pharmaceuticals Limited (NSE:REMUS)

Remus Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	215.37	85.03	34.34	10.26	8.12
Depreciation & Amortization	8.73	4.64	1.55	1.75	1.06
Other Amortization	0.23	0.13	-	-	-
Other Operating Activities	20.53	-3.93	-1.72	-0.66	0.85
Change in Accounts Receivable	-471.36	-19.33	6.89	-19.77	-2.83
Change in Inventory	-6.21	13.02	-4.39	-7.14	-4.02
Change in Accounts Payable	362.16	-15.07	14.97	48.01	21.13
Change in Other Net Operating Assets	-93.43	-11.36	-1.26	-4.07	-11.28
Operating Cash Flow	36.02	53.13	50.38	28.38	13.03
Operating Cash Flow Growth	-32.20%	5.46%	77.52%	117.86%	-
Capital Expenditures	-6.36	-27.32	-0.71	-0.66	-5.59
Cash Acquisitions	-93.37	-	-	-	-
Investment in Securities	-5.91	-175.48	-30.01	-0.67	-
Other Investing Activities	22.35	3.45	2.44	0.69	-
Investing Cash Flow	-89.43	-151.92	-45.45	-30.9	-5.59
Long-Term Debt Issued	-	77.51	-	-	0.87
Long-Term Debt Repaid	-65.03	-	-0.87	-0.8	-
Net Debt Issued (Repaid)	-65.03	77.51	-0.87	-0.8	0.87
Issuance of Common Stock	476.85	42.5	-	-	-
Common Dividends Paid	-5.89	-	-	-	-
Other Financing Activities	-162.27	-2.33	-0.87	-0.35	-0.23
Financing Cash Flow	243.66	117.69	-1.74	-1.15	0.64
Miscellaneous Cash Flow Adjustments	-	0	-	0	0
Net Cash Flow	190.26	18.9	3.18	-3.68	8.08
Free Cash Flow	29.67	25.81	49.67	27.72	7.43
Free Cash Flow Growth	14.93%	-48.03%	79.21%	272.81%	-
Free Cash Flow Margin	1.39%	5.72%	20.09%	14.74%	5.99%
Free Cash Flow Per Share	5.23	6.32	12.42	6.93	1.86
Cash Interest Paid	4.84	2.33	0.87	0.35	0.23
Cash Income Tax Paid	65.66	29.97	11.94	3.65	3.05
Levered Free Cash Flow	-210.09	7.45	42.87	24.7	-
Unlevered Free Cash Flow	-207.29	8.73	43.36	24.88	-
Change in Net Working Capital	384.67	35.43	-16.11	-16.53	-

Updated Nov 9, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.